NeuClone says pre-clinical results show the biosimilar of Janssen’s Stelara (ustekinumab) that it is developing with Serum Institute of India matches the psoriasis and Crohn’s disease brand “in both primary amino-acid sequence and three-dimensional folding”. The Australian firm is currently conducting process scale-up ahead of Phase I clinical trials scheduled for next year, while it also intends to meet with “potential commercialisation partners”.
“These results demonstrate our ability to create biosimilars using our ‘right from the start’ approach to biosimilarity, confirming each NeuClone...
